Identification of a novel TNRC18‐RARA fusion in acute promyelocytic leukemia lacking t(15;17)(q24;q12)/PML‐RARA,Molecular Carcinogenesis

当前位置： X-MOL 学术 › Mol. Carcinog. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Identification of a novel TNRC18‐RARA fusion in acute promyelocytic leukemia lacking t(15;17)(q24;q12)/PML‐RARA
Molecular Carcinogenesis ( IF 4.6 ) Pub Date : 2021-01-11 , DOI: 10.1002/mc.23276
Zheng Wang _{1,

2} , Lijun Wen ₁ , Ling Zhang ₁ , Xiaoyu Xu ₁ , Xiaoqian Chen ₁ , Li Yao ₁ , Man Wang ₁ , Zhen Shen ₁ , Guangquan Mo ₃ , Yao Wang ₃ , Dewan Zhao ₃ , Wei Cai ₃ , Jingzhi Shen ₃ , Xiaomeng Chi ₄ , Yi Xu ₁ , Zhao Zeng ₁ , Jinlan Pan ₁ , Changgeng Ruan _{1,

5} , Depei Wu _{1,

5} , Zhilin Jia ₃ , Suning Chen _{1,

5}

Affiliation

Acute promyelocytic leukemia (APL) is a unique disease entity in acute myeloid leukemia, characterized by PML‐RARA fusion gene, which is generated by chromosomal translocation t(15;17)(q24;q21). We identified TNRC18‐RARA as novel RARA fusion in resembling APL. Our study highlights the importance of combining multiple molecular techniques to characterize and optimally manage APL lacking classic t(15;17)(q24;q12)/PML‐RARA fusion.

中文翻译：

在缺乏t（15; 17）（q24; q12）/ PML-RARA的急性早幼粒细胞白血病中鉴定新型TNRC18-RARA融合体

急性早幼粒细胞白血病（APL）是急性髓性白血病中独特的疾病实体，其特征是PML-RARA融合基因是由染色体易位t（15; 17）（q24; q21）产生的。我们将TNRC18-RARA识别为类似于APL的新型RARA融合体。我们的研究突出了结合多种分子技术来表征和最佳管理缺乏经典t（15; 17）（q24; q12）/ PML-RARA融合的APL的重要性。

更新日期：2021-01-19

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>